Trials / Completed
CompletedNCT05245578
Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male Subjects
Skin Irritation and Phototoxicity Study of KX01 Ointment 1% in Japanese Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- PharmaEssentia · Industry
- Sex
- Male
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Skin Irritation and Phototoxicity Study of KX01 Ointment 1% in Japanese healthy male subjects
Detailed description
A baseline evaluation of the patch sites will be performed immediately prior to application of the patches to ensure that no conditions, markings, or coloration of the skin will interfere with interpretation of the study results. A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01KX2-391 ointment 1% and 2 sites for Placebo vehicle ointment. One set (KX01 ointment 1% IP and Placebo ointment vehicle patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions. The distance between the patches will be no less than one centimeter. The numbering of the test sites will remain the same throughout the study. The sites will be marked with an indelible, surgical marker.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KX01 ointment 1% | A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions. |
| DRUG | Placebo ointment | A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions. |
Timeline
- Start date
- 2021-11-16
- Primary completion
- 2021-11-22
- Completion
- 2022-01-12
- First posted
- 2022-02-18
- Last updated
- 2022-02-18
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05245578. Inclusion in this directory is not an endorsement.